Evidence map›Paper›PMID 29405257›Full record

ArticleThe British journal of dermatology2018

Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?

T Kanni, O Zenker, M Habel, N Riedemann, E J Giamarellos-Bourboulis

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in The British journal of dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
11.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 79 citations in OpenAlex.

  1. European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025
    Guideline
  2. Pooled it
  3. Trial
  4. Article
  5. Diabetes status is associated with greater disease severity in hidradenitis suppurativa.JID innovations : skin science from molecules to population health · 2026
    Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

T KanniFourth Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
O ZenkerInflaRx, Jena, Germany.
M HabelInflaRx, Jena, Germany.
N RiedemannInflaRx, Jena, Germany.
E J Giamarellos-BourboulisFourth Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.ORCID 0000-0003-4713-3911
Inflarx (Germany) · DENational and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite the heavy purulence observed in hidradenitis suppurativa (HS), the kinetics of complement anaphylatoxins acting to prime chemotaxis of neutrophils has not been studied.

objectivesTo explore complement activation in HS.

methodsCirculating concentrations of complement factor C5a, as well as of membrane attack complex C5b-9, were determined in the plasma of 54 treatment-naïve patients and of 14 healthy controls, as well as in the pus of seven patients. Results were correlated with Hurley stage and International Hidradenitis Suppurativa Severity Score. Peripheral blood mononuclear cells (PBMCs) were isolated from seven patients with Hurley stage III HS and seven healthy volunteers and stimulated in the presence of 25% of plasma for the production of tumour necrosis factor-α (TNF-α).

resultsCirculating C5a and C5b-9 were significantly greater in patient than in control plasma; however, concentrations in pus were very low. Circulating C5a levels exceeding 28 ng mL

conclusionsSystemic complement activation occurs in HS and may be used as a surrogate biomarker of HS. C5a stimulates overproduction of TNF-α and may be a future therapeutic target.

Indexed as

AdultBiomarkersChemotaxis, LeukocyteComplement ActivationComplement C5aComplement C5bFemaleHidradenitis SuppurativaHumansMaleMiddle AgedNeutrophilsSeverity of Illness IndexTumor Necrosis Factor-alphaBiomarkersComplement C5aComplement C5bTNF protein, humanTumor Necrosis Factor-alpha

Identifiers

PMID29405257
OpenAlexW2790731337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.